Capecitabine plus lenvatinib for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two oral drugs, capecitabine and lenvatinib, in people with advanced colorectal cancer that has stopped responding to three common chemotherapy drugs. It aims to see if this new combination can help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced colorectal cancer that has stopped responding to irinotecan, oxaliplatin, and fluoropyrimidine chemotherapy.
- You must be 19 years or older and give written consent.
- You must be in reasonably good health, with adequate blood counts, kidney and liver function.
- You must not be pregnant or breastfeeding, and if able to have children, you must use effective birth control.
- You must not have another active cancer, uncontrolled infection, or serious heart or bleeding problems.
- You must not have known severe allergies to the study drugs or certain other conditions like DPD deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new combination drug, LBL-024, for people with colorectal cancer that has spread to other parts of the body. The goal is to see if the combination can shrink tumors or slow down the cancer's growth.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
Hear when a new Advanced Colorectal Cancer (Part 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.